Obermatt
See Similar Stocks →

Iovance Biotherapeutics

NMQ:IOVA · US4622601007
BiotechnologyMedium

360

56
Profit price28
Cash yield1
Price/Sales82
EV / Gross Profit40
Price/Book46
Return on Capital44
Cash Return on Capital45
Return on Equity45
EBIT Margin10
Gross Profitability55
Accruals56
Owner Earnings Margin40
Sales growth49
Profit growth23
Reinvestment12
Price momentum75
Debt load67
Refinancing94
Debt Payback1
Liquidity86
Analyst ratings17
Opinion Changes23
Price Target Upside88
Market mood50
Value Creation10/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Iovance Biotherapeutics clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryBiotechnology
SizeMedium
TypePublic Company
ExchangeNASDAQGM
Founded2007
Employees865
Websiteiovance.com
ISINUS4622601007
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Stem Cell TherapyImmunologyOncologyGeneticsBiotechnologyHealth CarePharmaceuticalTherapeutics

Description

Iovance Biotherapeutics, Inc. (Iovance) operates as a commercial-stage biopharmaceutical company. The company is pioneering a transformational approach to treating cancer. The company's mission is to be the global leader in innovating, developing, a…

Analysis

Middle-of-the-road

Iovance Biotherapeutics, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is adequate. The company scores 10/20 on our value-creation score: creating some value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
80
2026

All-time high

80

Jun 2026

All-time low

79

Mar 2026

Average rank

80

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
82
—
—
—
Price/Earnings
78
—
—
—
Price/Book
46
—
—
—
Dividend Yield
—
—
—
—
Value (overall)
97
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Iovance Biotherapeutics with its peers
Day One Biopharmaceuticals
NSQ:DAWN
39
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Eledon Pharmaceuticals
NAQ:ELDN
16
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Cullinan Therapeutics
NSQ:CGEM
61
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Cogent Biosciences
NSQ:COGT
54
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Century Therapeutics
NAQ:IPSC
45
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Kyverna Therapeutics
NSQ:KYTX
6
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →